Choose any two compounds below to see them side by side. Each comparison page lines up the level of evidence behind each one, the registered clinical trials, and where each stands with regulators, so the differences are easy to see in one place.
This is a side-by-side of what is documented, not a ranking. Different compounds are studied for different things, in different people, at different amounts. A row that looks stronger for one compound does not make it the better choice for anyone.
| Matrixyl | SNAP-8 | |
|---|---|---|
| Highest evidence tier on the page | E1 Approved-label evidence FDA or EMA approved labelling for a specific indication. | E4 Preclinical only Animal or in vitro work. Not demonstrated in humans. |
| Regulatory status | Not stated | Registered cosmetic ingredient (CosIng, EU) only; no drug/biologic approval; not evaluated by FDA as a drug |
| Research area | Cosmetic and topical | Cosmetic and topical |
| Regulator-approved dose on file | No approved dose | No approved dose |
| Molecular formula | Sources conflict: Wikipedia and a PubChem "Palmitoyl-Pentapeptide-4" record report C39H75N7O10 (MW ≈802 g/mol); at least one commercial chemical-supplier summary instead lists C32H54N6O9S (MW ≈703 g/mol). This entry follows the Wikipedia/PubChem figure as the more consistently cross-referenced value but flags the conflict rather than presenting either as unquestionably correct. | C41H70N16O16S (per CAS 868844-74-0 as listed by ChemicalBook and Chemsrc), a separate PubChem search result for "Acetyl octapeptide-3" (CID 71587832) instead shows C42H72N16O15S; this discrepancy is unresolved, see Meta::NOT_KNOWN |
| Molar mass | ≈802.1 g/mol (as reported by Wikipedia, a PubChem record, and the CIR safety assessment; see Formula note on a conflicting lower value found elsewhere) | ~1075.16 g/mol (per CAS 868844-74-0 sources; not independently reconciled against the differing PubChem CID 71587832 formula) |
| CAS number | 214047-00-4 (one source also lists 521091-64-5 in connection with this ingredient; this entry could not independently resolve whether that second number reflects a different salt/lot designation or a data conflict, and flags it rather than silently omitting it) | 868844-74-0 (widely cited across chemical vendor/database sources for SNAP-8 / Acetyl Octapeptide-3, see Meta::NOT_KNOWN for a documented naming/identifier conflict) |
| Registered trials on this site | None linked yet | None linked yet |
| What is not known | The exact pure-peptide percentage used in the primary published human photoaging study (Robinson et al., 2005) could not be independently confirmed from the secondary sources reviewed for this entry. The magnitude of any visible cosmetic effect from independent, non-manufacturer-affiliated human trials has not been clearly... | A genuine, unresolved conflict exists in publicly available chemical-identifier data for SNAP-8. The CAS number nearly universally cited for SNAP-8/Acetyl Octapeptide-3 by chemical vendors (868844-74-0) is listed with the molecular formula C41H70N16O16S and molecular weight ~1075.16 g/mol by both ChemicalBook and Chemsrc, and both sources... |
Full pages: Matrixyl and SNAP-8. See also the clinical trial tracker and how we grade evidence.
Educational reference, not medical advice. Trial data from ClinicalTrials.gov. Everything else is drawn from the compound pages on this site, each of which cites its sources.
Most requested comparisons
These are the pairings readers look for most often. Each opens a full side-by-side page.
Weight management compounds
- Retatrutide vs Tirzepatide
- Semaglutide vs Tirzepatide
- Retatrutide vs Semaglutide
- Retatrutide vs Survodutide
- Cagrilintide vs Semaglutide
- Orforglipron vs Semaglutide
- Mazdutide vs Tirzepatide
- Cagrilintide vs Eloralintide
- LY4086940 vs Retatrutide
- LY4086940 vs Orforglipron
Growth hormone related peptides
- Ipamorelin vs Sermorelin
- Sermorelin vs Tesamorelin
- CJC-1295 (no DAC) vs Ipamorelin
- CJC-1295 with DAC vs Ipamorelin
Repair and recovery
Longevity, mitochondria and brain
How to read a comparison
A side-by-side table can make two compounds look equally proven when they are not. Keep these points in mind as you read.
- Evidence level matters more than the headline. Every compound is placed on the same six-tier scale, from published human clinical trials down to community reports. A compound with large human trials and one with only animal studies are not comparable, even when both appear in the same table.
- Registered trials show what is being tested. A trial listed on ClinicalTrials.gov tells you a question is being studied, not that the answer is known. Check the status and phase. You can browse every tracked study on the clinical trial tracker and see recent registry updates in the trial changes feed.
- Regulatory status is specific to a formulation and a country. Approval of one product does not mean every version of that compound is approved.
- Different populations and doses limit direct comparison. Results from separate trials, run in different people over different periods, cannot be lined up as if they came from a head-to-head study unless a comparison page says a head-to-head study exists.
Frequently asked questions
Which compound is better?
These pages do not rank compounds or tell anyone what to use. They show what the published and registered evidence says about each one so you can see where the evidence is strong and where it is thin.
Why are some comparisons mostly empty on one side?
Many popular peptides have little or no human trial data. When that is the case, the comparison says so plainly rather than filling the gap with community claims.
Can I compare doses here?
Reported amounts are documented on each individual peptide page, with the source and evidence tier for every figure. If you need to work out concentrations, the reconstitution calculator is a math tool only and does not suggest an amount.
Where can I see every compound?
The full peptide library lists every entry,.
PeptideBlog is an educational reference compiled from public sources. It is not medical advice, and nothing here is a recommendation for or against any compound.